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Abstract
Backgrounds: A pancreatic fistula (PF) is the most relevant complication after a pancreaticoduodenec-
tomy (PD). This retrospective multicentric study attempts to elucidate the risk factors and complications
of a PF in a large cohort of patients undergoing a PD for ductal adenocarcinoma.
Methods: Using a survey tool, clinical data of 1325 patients undergoing a PD for ductal adenocarcinoma
at 37 institutions, between January 2004 and December 2009, were collected. Peri-operative risk factors
associated with PF and its association with morbidity and mortality were assessed. Morbidity and PF
were graded according to the ISGPF (International Study group for pancreatic fistula) definition and the
Dindo–Clavien classification.
Results: Overall PF, mortality, morbidity and relaparotomy rates were 14.3%, 3.8%, 54.4% and 11.7%,
respectively. PF occurred more frequently after a pancreaticojejunostomy (PJ) compared with a pancrea-
ticogastrostomy (PG) (16.8% vs. 10.4%; P = 0.0012). Independent risk factors for PF by multivariate
analysis were absence of pre-operative diabetes (P = 0.0014), PJ reconstruction (P = 0.0035), soft
pancreatic parenchyma (P < 0.0001) and low-volume centre (P = 0.0286). Clinically relevant PF (grade B
and C) and severe complications (Dindo–Clavien grade IIIB, IV, V) were significantly more frequent after
PJ than PG (71.6% vs. 28.3%; P = 0.030 and 24.8% vs. 19.1%; P = 0.015, respectively). Overall mortality
and relaparotomy rates were similar after PG and PJ.
Conclusions: A soft pancreatic parenchyma, the absence of pre-operative diabetes, PJ and low-volume
centre are independent risk factors for PF after PD for ductal adenocarcinoma. A significantly higher
incidence and clinical severity of PF are associated with PJ.
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Introduction
In spite of more effective chemotherapy regimens, a pancreati-
coduodenectomy (PD) remains the only curative option for
patients presenting with resectable ductal adenocarcinoma of the
pancreatic head. As a result of improvements in surgical technique
and in peri-operative care, the 5-year survival rates for patients
undergoing a R0 resection for localized pancreatic cancer have
approached 25%.1–5 However, in spite of improvements in long-
term survival and mortality, post-operative morbidity still
This manuscript was presented at the 10th World IHPBA Congress, Paris,
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remains high with rates reported between 30% to 50% in large
series.6–8 Of these, a post-operative pancreatic fistula (PF) still is
the clinically most relevant complication after PD with an inci-
dence ranging from 9.9% to 28.5%.9 It is often associated with
the development of life-threatening intra-abdominal complica-
tions such as sepsis, abscesses, early or delayed haemorrhage, the
need for a relaparotomy and death.10 Known risk factors for PF
are associated with patient, disease, procedure and surgeon-
related factors. Among these obesity,11 diabetes,12,13 pre-operative
jaundice,14 and malnutrition constitute patient-related factors
whereas ampullary or duodenal disease,15,16 high pancreatic juice
output,17 soft pancreatic parenchyma,18 fatty pancreatic tex-
ture11,19,20 and a small pancreatic duct diameter6 are disease-related
factors. Increased intra-operative blood loss,21 longer operative
times,12 low volume surgeon16,22–24 and type of pancreatico-enteric
reconstruction25–28 constitute procedure and surgeon-related
factors.
Several previous studies have reported a decreased risk of PF in
patients undergoing PD for ductal adenocarcinoma compared
with other diseases citing the presence of obstructive jaundice,
hard pancreatic parenchyma and a dilated pancreatic duct as
favourable factors for better outcomes after pancreatic head
resections.16,18,29–34 However, studies specifically focusing on post-
operative outcome and risk factors for PF after PD for ductal
adenocarcinoma are lacking. The aim of the present multi-centric
study was to study the occurrence of PF after PD for ductal adeno-
carcinoma, its risk factors and association with morbidity.
Patients and methods
Patients selection
A multicentric study of PF after PD was promoted by three
experienced pancreatic surgeon members (J.R.D., F.P. and P.B.)
of the French Association of Surgery (Association Française de
Chirurgie) in 2009. Patients who underwent a PD between 1
January 2004 and 31 December 2009 were eligible for this ret-
rospective study. Using a standard questionnaire, pre-operative,
intra-operative and post-operative data (early and late out-
comes) were collected from 37 responding institutions (France,
34; Belgium, 1; Monaco, 1; and Switzerland, 1). Only patients
with pancreatic ductal adenocarcinoma diagnosed on the final
pathology constituted the study population. To ascertain
uniform interpretation of the survey data35, all data sheets were
reviewed by the main study authors (J.R.D., F.P. and P.B.) before
transfer to the database.
Operative technique
Several technical variations of PD, including pylorus preservation,
the use of a trans-anastomotic stent and a pancreaticogastrostomy
(PG) compared with a pancreaticojejunostomy (PJ) were per-
formed according to the surgeons’ preferences. The prophylactic
use of somatostatin analogues varied among centres according to
local guidelines. Segmental or lateral vascular resections of the
superior mesenteric vein, portal vein, superior mesenteric artery
and/or hepatic artery and en-bloc resection of the colon, kidney,
liver and stomach were included in the study population. The
extent of a lymphadenectomy depended on the surgeon and
centre preferences. A standard lymphadenectomy was defined as
removal of N1 lymph nodes according to the TNM-UICC 2002
classification.36 An extended lymphadenectomy was defined as
standard plus removal of interaortico-caval lymph nodes with
circumferential clearance of the origin of the celiac trunk and
superior mesenteric artery.
Definitions
In-hospital mortality and morbidity were limited to occurrences
within 60 days after surgery. The severity of complications was
graded using the Dindo–Clavien classification system.37 A severe
complication was defined as grade IIIb or above. A PF was defined
using the current classification provided by the International
Study group (ISGPF: grade A, B, C). Therefore a PF was defined as
any measurable drainage from an operatively placed drain on or
after post-operative day 3 demonstrating amylase levels greater
than three times the upper limit of the normal serum amylase
level.9 Grade B and C PF were considered clinically significant. PF
were assessed using the Dindo–Clavien’s classification system.38
Intra-operatively, the parenchymal pancreatic texture was defined
by the operating surgeon as soft, normal or fibrous at the time of
the operation. According to the North American standards, high-
volume centres were defined as equal or greater than 20 PDs
performed per year, medium-volume centres performing between
10 and 19 PDs per year and low-volume centers performing less
than 10 PDs per year.39,40
A diagnosis of PF was obtained clinically during reoperation,
radiologically and by laboratory tests as described above. Intra-
abdominal collections were diagnosed by computed tomography.
A digestive tract haemorrhage was defined as blood from the
nasogastric tube and confirmed by endoscopy or angiography. An
intra-abdominal haemorrhage was defined by the presence of
blood in abdominal drains, on angiography or both. Medical
complications included septic shock, deep vein thrombosis, and
cardiac, pleuropulmonary, and neurologic events.
End points
The main post-operative outcomes were the presence of a PF and
its association with mortality and morbidity. Secondary endpoints
consisted of risk factors for post-operative PF, mortality and mor-
bidity. They included: patient age, gender, body mass index (BMI),
the presence of diabetes, the use of pre-operative biliary drainage,
American Society of Anesthesiologist (ASA) class, the use of pre-
operative neo-adjuvant treatment, the need for a red blood cell
(RBC) transfusion, pylorus preservation, the type of pancreati-
coenteric reconstruction, size of the pancreatic duct, texture of the
pancreatic parenchyma, associated vascular resection, the number
of lymph nodes harvested, the use of a biological glue, the use of
HPB 47
HPB 2014, 16, 46–55 © 2013 International Hepato-Pancreato-Biliary Association
abdominal drains, the use of pancreatic ductal stenting, associated
multivisceral resections and centre volume.
Statistical analysis
Values were expressed as mean  standard deviation (SD). The
Mann-Whitney U-test, chi-square test, Fisher’s exact test or Stu-
dent’s t-tests were used as appropriate. All variables reaching a P <
0.15 in the univariate analysis were included in multivariate analy-
sis using a logistic regression model. Results were presented as
relative risk (RR) with 95% confidence intervals. Significance was
established at P < 0.05. Statistics were performed using the SPSS
17.0.1 system (SPSS Inc., Chicago, IL, USA).
Results
Patients characteristics
In total, 1325 patients underwent a PD for ductal adenocarcinoma
in the period study (754 women and 571 men) with a mean age of
64.9  10.1 years (range, 25–87) and a mean body mass index
(BMI) of 24.3  4.2 (range, 11.2–46.9). Among them, 428
(32.30%) were older than 70 years, 224 (16.90%) had diabetes
mellitus, 972 (73.55%) had pre-operative jaundice and 445
(33.58%) had pre-operative biliary drainage. Pre-operatively, 142
(10.7%) patients underwent radiotherapy and/or chemotherapy
with 39 patients undergoing chemotherapy only. A mesenterico-
portal vein resection was performed in 360 patients (27.16%) of
which 133 had a non-segmental lateral resection. An extended
lymphadenectomy and pylorus-preservation was performed in
303 patients (22.86%) and 163 patients (12.3%), respectively. A
pancreaticojejunostomy and PG was performed in 733 (55.3%)
and 563 patients (42.5%), respectively. The type of reconstruction
was not specified in 29 patients (2.2%). The pancreatic duct diam-
eter was < 3 mm in 411 patients, 4 and 6 mm in 344 patients, 7 and
9 mm in 107 patients, >10 mm in 85 patients and not reported in
378 patients (28.5%). The pancreatic texture was reported as
fibrous in 640 patients, normal in 150 patients, soft in 357 patients
and not specified in 149 patients. The majority of patients under-
went duct to mucosa anastomosis (n = 811) and a transanasto-
motic stent was used in 296 patients. In patients who underwent
an associated SMV-PV resection, PJ and PG was performed in 195
patients (54.2%) and 160 patients (44.4%), respectively. In five
patients (1.4%), the type of reconstruction was not specified. One
or more abdominal drains were used in 1267 (95.6%) patients,
none in 12 patients and not specified in 46 patients. Octreotide
analogues and biological glue were used in 534 (40.3%) and 72
(5.4%) patients, respectively.
Comparison of the study population according
to the pancreatic anastomosis and the texture
of pancreatic parenchyma
An invaginating anastomosis rather than a duct-to-mucosa tech-
nique was used more often in PG compared with PJ (318 vs. 62,
P < 0.001).The anastomotic stenting rate was similar for both PG
and PJ. The rate of invagination and stenting was significantly
higher in the presence of a normal or soft pancreas and a small
diameter pancreatic duct (Table 1).
Early post-operative outcomes
Mortality
Overall mortality was 3.8% (51 patients). The main surgical
causes of death were intra-abdominal bleeding (15 patients), PF
(13 patients), sepsis related to an intra-abdominal collection (10
patients), digestive bleeding (7 patients) and a bilio-digestive leak
(2 patients). There were no differences in mortality according to
the type of pancreatico-enteric reconstruction (4.1% in PJ vs.
3.7% in PG; P > 0.7).
Morbidity
Overall morbidity was 54.4% (721 patients). A total of 1180 com-
plications occurred in 721 patients: an abdominal abscess in 215
Table 1 Correlation between pancreatic remnant characteristics and type of pancreaticoenteric reconstructiona
Invagination (n = 380) P Stenting
(n = 296)
P
Type of anastomosis performed 0.001 NS
PG 318 128
PJ 62 168
Texture of the pancreatic remnant 0.001 0.0001
Fibrotic 185 113
Normal 114 115
Soft 45 36
Size of the pancreatic duct <0.01 <0.05
3 mm 99 88
4–6 mm 75 77
7–9 29 33
10 28 13
aValues are number of patients for which the data were available.
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patients, PF in 189 patients, DGE in 172 patients, intra-abdominal
bleeding in 89 patients, intestinal bleeding in 67 patients, biliary
fistula in 41 patients, gastric or duodeno-jejunal fistula in 6
patients, pulmonary or cardiovascular complications in 119
patients and other complications in 282 patients. Four hundred
sixteen patients had one complication and 305 patients experi-
enced more than one complication. The overall morbidity rate did
not differ according to the type of pancreatico-enteric reconstruc-
tion (52.5% after PG vs. 55.7% after PJ; P = 0.7). Severe compli-
cations, defined as grade IIIb, IV and V according to the Dindo–
Clavien classification, were significantly more frequent after PJ
than PG (24.8% vs. 19.1%, P = 0.0156; Table 2). This did not lead
to increased readmission rates in patient undergoing PJ (PJ 11.3%
vs. PG 13.0%; P = 0.35).
Pancreatic fistula and related morbidity
A total of 189 patients experienced a PF (14.3%) of which 41
patients had a grade A fistula, 97 had a grade B fistula and 51 had
a grade C fistula.9 The PF rate was significantly higher (123, 16.8%
vs. 59, 10.4%; P < 0.001) and more severe after PJ compared with
PG (71.6% vs. 28.3%; P < 0.03), respectively (Table 3). Compared
with patients who did not develop PF, patients with PF had a
significantly higher rate of septic complications (41.5% vs. 13.1%;
P < 0.0001), DGE (20.3% vs. 12.0; P < 0.002); intrabdominal
bleeding (20.3% vs. 5.0%; i < 0.0001), digestive bleeding (12.6 vs.
3.9%; P < 0.001), cardiopulmonary complications (13.8 vs. 8.5%;
P < 0.02), rehospitalization (17.2% vs. 11.3%; P < 0.02) and overall
mortality (13.3% vs. 2.3%; P < 0.0001).
Relaparotomy
During the first 30 post-operative days, 155 patients (11.7%)
underwent a relaparotomy. Data for the cause of relaparotomy
were available for 143 patients. Thirty patients had two
relaparotomies, 30 had three relaparotomies and 2 had four
relaparotomies in the post-operative period. A PF was the second
most common cause for a relaparotomy after a haemorrhage. The
relaparotomy rate for PF was lower after PG (n = 4) compared
with PJ (n = 21). During reoperation for PF, a completion pan-
createctomy was performed in 11 patients, redo PJ anastomosis in
one, conversion from PJ to PG in one and drainage of peri-
anastomotic fluid collections in 15 patients.
Analysis of risk factors
Univariate and multivariate analysis of risk factors for morbidity,
mortality, PF, digestive and abdominal bleeding and DGE are
shown in Tables 4 and 5. Univariate analysis showed that higher
post-operative mortality was associated with female gender, ASA
status III/ IV, intra-operative RBC transfusion > 2, use of a transa-
nastomotic drain and the occurrence of a post-operative PF. Mul-
tivariate analysis showed that the occurrence of a PF, a high ASA
status and intra-operative RBC transfusion > 2 units were inde-
pendent risk factors for overall mortality.
Univariate analysis showed that higher post-operative overall
morbidity was related to male gender, PDs performed in a low
volume centre, the use of pre-operative neo-adjuvant treatment,
a intra-operative RBC transfusion > 2 units, normal pancrea-
tic texture and the use of a pancreatic ductal stent. At multiva-
riate analysis male gender, a RBC transfusion > 2 units, normal
Table 2 Post-operative complications after a pancreaticoduodenectomy (PD) according to the type of pancreaticoenterico recostruction
performeda
Clavien Pancreatic
fistula
Sepsis/
collections
Intrabdominal
haemorrhage
Cardio/
pulmonary
Digestive
haemorrhage
DGE Others
PJ
(n = 733)
Mild
(I, II,IIIA)
123 85 128 95 54 19 64 39 36 21 109 105 149 117
Severe
(IIIB,IV,V)
38 33 35 25 15 4 32
PG
(n = 563)
Mild
(I, II,IIIA)
59 48 84 64 33 6 50 34 30 17 63 62 130 110
Severe
(IIIB,IV,V)
11 20 27 16 13 1 20
Total
(n = 1296)
Mild
(I, II,IIIA)
182 (14%) 133 212 (16%) 159 87 (7%) 25 114 (9%) 73 66 (5%) 38 172 (13%) 167 279 (22%) 227
Severe
(IIIB,IV,V)
49 53 62 41 28 5 52
aValues are the number of patients for which the data were available.
Table 3 Post-operative pancreatic fistula grading according to the
type of pancreaticoenteric reconstruction performed
Grade
A B C
PJ
(n = 733)
22 63 38
PG
(n = 563)
19 29 11
Total PF
(n = 189)a
41 (21.7%) 92 (48.7%) 49 (25.9%)
aData of pancreaticoenterico reconstruction in seven patients presenting
with PF was not reported.
PJ, pancreaticojejunostomy; PG, pancreaticogastrostomy; PF, pancre-
atic fistula.
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Table 4 Univariate analysis of risk factors for post-operative mortality, morbidity and pancreas-related complicationsa
Mortality
(n = 51)
Morbidity
(n = 721)
Pancreatic
fistula
(n = 189)
Intra-abdominal
haemorrhage
(n = 89)
Digestive
haemorrhage
(n = 67)
DGE
(n = 172)
Yes P Yes P Yes P Yes P Yes P Yes P
Age 0.6 0.0919 0.2656 0.1132 0.6769 0.0080
70 32 468 120 66 46 357
>70 18 248 68 22 20 71
Gender 0.0215 0.0416 0.0669 0.2354 0.0462 0.7261
Male 14 329 93 33 21 72
Female 37 392 96 56 46 100
Centre volume 0.9778 0.0065 <0.0028 0.3691 0.2874 0.0001
10 19 305 97 37 27 99
10–20 22 293 32 40 32 35
>20 10 123 60 12 8 38
Body mass index 0.4156 0.6436 0.0895 0.0844 0.0651 0.3602
25 23 371 91 35 42 97
>25 18 220 71 32 15 51
Pre-operative diabetes 0.1671 0.6377 0.0072 0.0998 0.0776 0.5356
Absent 41 536 156 74 54 133
Present 5 119 20 10 6 27
ASA score 0.0136 0.1785 0.0605 0.0807 0.1709
I 7 126 42 20 12 38 0.9275
II 23 378 103 36 36 103
III 11 115 15 13 9 30
IV 1 2 1 1 1 1
Pre-operative biliary drainage 0.8521 0.1802 0.2087 0.5289 0.0075 0.6822
No 34 473 130 61 54 107
Yes 17 232 57 28 13 60
Neoadjuvant chemotherapy 0.4976 0.0065 0.0654 0.3678 0.0902 0.3643
No 47 659 176 82 64 157
Yes 2 62 13 7 3 15
Pylorus-preserving PD 0.6888 0.1284 0.8070 0.8169 0.0111 0.0388
No 42 618 161 76 52 159
Yes 7 98 24 10 15 13
Type of pancreato-enteric anastomosis 0.7019 0.2483 0.0012 0.2830 0.7348 0.0529
PJ 29 409 123 54 36 109
PG 20 296 59 33 30 63
Mesenterico-portal vein resection 0.0707 0.8338 0.0194 0.3270 0.1441 0.8236
No 30 517 148 67 53 122
Yes 19 194 38 20 13 48
Arterial resection 0.1503 0.9553 0.9177 0.1363 0.3099 0.0816
No 49 709 185 86 65 172
Yes 2 11 3 3 2 0
Associated multi-visceral resection procedure 0.7853 0.0663 0.0015 0.1173 0.7391 0.5673
No 47 650 162 82 64 163
Yes 3 43 18 7 3 9
Number of lymph nodes harvested 0.7052 0.3881 0.4345 0.7145 0.0307 0.0116
20 28 445 118 57 48 120
>20 19 258 64 32 16 49
RBC transfusion 0.0276 0.0208 0.5102 0.3142 0.0657 0.3859
2 10 127 153 75 52 148
>2 15 100 19 14 13 24
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pancreatic parenchyma and a low-volume centre were independ-
ent risk factors for overall morbidity.
Univariate analysis showed that a higher risk of PF was conferred
by the absence of pre-operative diabetes, PJ reconstruction, a low-
volume centre,-associated resection of the mesenterico-portal axis
or a multivisceral resection and soft texture of the pancreatic
parenchyma. There was a trend towards a higher PF rate in men, in
patients with a BMI > 25 and in patients receiving pre-operative
neo-adjuvant treatment. At multivariate analysis, the presence of a
soft pancreatic parenchyma, PJ reconstruction, the absence of pre-
operative diabetes, administration of somatostatin analogues and a
low-volume centre were independent risk factors for PF.
Multivariate analysis showed that PF was associated with a
higher risk of mortality, morbidity, abdominal and intestinal
bleeding and DGE. (Table 5)
Discussion
This multicentric retrospective study in 1325 patients revealed the
key independent risk factors for the development of a PF after PD
for adenocarcinoma of the pancreas. The occurrence of a PF after
PJ was associated with a greater clinical severity and a higher rate
of major post-operative morbidity compared with PG. PD con-
tinues to be a challenging and substantially morbid procedure.
The overall mortality and morbidity rates observed in this study
are in the range of what is reported in several single centre and
multicentre studies.4,41–43
A PF remained the leading cause of lethal complications in this
study. The majority of deaths were directly attributable to PF
associated with intra-abdominal, intestinal bleeding and sepsis.
Patient selection and surgical techniques devoted to minimize
intra-operative bleeding remain important factors in minimizing
the peri-operative mortality from this operation. Our multivariate
analysis for mortality found that PF, a high ASA class (III–IV) and
increased transfusion rate were independent risk factors. These
findings suggest that patient selection is key in balancing the risk
and benefits of PD in patients with adenocarcinoma.
An obvious relationship exists between PF and the occurrence
of other complications such as DGE, bleeding and sepsis.18,44,45
Our study supports this strong relationship and identified PF as
an independent risk factor for the occurrence of post-operative
intra-abdominal, intestinal bleeding and DGE.
In the present study, the investigators selected a homogenous
group of patients exclusively operated on for ductal adenocarci-
noma of the pancreatic head to better evaluate the risk factors and
the association of PF after PD. The pancreatic remnant character-
Table 4 Continued
Mortality
(n = 51)
Morbidity
(n = 721)
Pancreatic
fistula
(n = 189)
Intra-abdominal
haemorrhage
(n = 89)
Digestive
haemorrhage
(n = 67)
DGE
(n = 172)
Yes P Yes P Yes P Yes P Yes P Yes P
Texture of pancreatic remnant 0.3569 <0.0001 <0.0001 <0.0001 0.1607 0.0035
Soft 24 322 122 56 30 97
Fibrous 23 307 47 23 26 75
Pancreatic drain 0.0351 0.0326 0.4744 0.0387 0.8855 0.0097
No 3 151 32 12 11 25
Yes 14 176 50 29 14 55
Pancreatic fistula <0.0001 <0.0001 NA <0.0001 0.0002 0.0074
No 27 0 NA 56 47 136
Yes 24 189 NA 33 20 36
Use of biological glue 0.6654 0.7229 0.0724 0.0873 0.9337 0.0001
No 5 174 35 14 15 32
Yes 2 47 16 8 4 24
Prophylactic octreotide administration 0.1697 0.2033 <0.0001 0.4760 0.5629 0.6501
No 17 306 62 32 27 80
Yes 24 303 103 35 29 69
Use of abdominal drainage 0.5851 0.1363 0.8241 0.0693 0.6170 0.1783
No 1 20 6 0 3 3
Yes 47 692 180 85 62 169
Type of gasytro-jejunal anastomosis 0.0522 0.1441 0.0490 0.0216 0.2004 0.0017
Antecolic 12 242 52 22 17 41
Transmesocolic 38 445 119 64 40 114
aValues are the number of patients for which the data were available.
Statistical significance indicated in bold.
DGE, delayed gastric emptying; ASA, American Society of Anesthesiologist; PD, pancreaticoduodenectomy; RBC, red blood cells;
NA, not applicable.
HPB 51
HPB 2014, 16, 46–55 © 2013 International Hepato-Pancreato-Biliary Association
istics, which are directly correlated with underlying pancreatic
disorder influences the early post-operative outcome, in particular
the incidence and severity of PF formation. It has been shown that
patients undergoing PD for ampullary, biliary or neuoroendocrine
tumours have most commonly an undilated pancreatic duct, thin
pancreatic body and a non-fibrotic pancreatic parenchyma, condi-
tions that greatly increase the risk of PF.15 However, PF incidence
and its association with morbidity and mortality in patients
uniquely presenting with pancreatic adenocarcinoma for PD is less
well understood. Lin et al.18 and Winter et al.4 reported a PF rate of
5% in patients undergoing PD for pancreatic adenocarcinoma
compared with a 15.4% to 18.4% rate in patients operated on for
distal cholangiocarcinoma, duodenal carcinoma and ampullary
cancer. In these reports up to 75% of patients with adenocarcinoma
had pre-operative jaundice.4 In the present study, the PF rate after
PD for pancreatic ductal adenocarcinoma was 14% which is com-
parable to rates recently reported by large single institutions.46,47
The association between the presence of pre-operative diabetes and
PF is still under debate. In a retrospective study, Srivasatva12 iden-
tified diabetes as an independent risk factor for PF after PD for
benign and malignant periampullary lesions. Chu et al.48 reported
similar results in patients presenting with pancreatic ductal adeno-
carcinoma with a higher PF rate in diabetic patients compared with
non-diabetics (10.3% vs. 3.7%). Pre-operative diabetes remains an
independent risk factor for PF even when stratified to age, comor-
bidities, BMI, pre-operative albumin level, operation type, opera-
tive time and pancreatic parenchymal quality.
Lin reported that patients without a history of diabetes were at
a significantly higher risk for post-operative PF compared with
diabetics patients (12.0% vs. 7.7%)18 A possible explanation for
these findings was reported more recently by Mathur et al.20
Patients with PF had a lower rate of diabetes (13% vs. 33%) and a
significantly increased amount of pancreatic fat with less fibrosis
and a smaller pancreatic duct. They concluded that patients with
diabetes therefore may have less pancreatic fat and a higher
amount of pancreatic fibrosis, protecting them from PF forma-
tion.20 Similarly, in this study the absence of pre-operative diabetes
was an independent risk factor for PF. These results supports the
hypothesis that patients with diabetes more often present with a
firm pancreatic texture leading to a lower PF rate after PD.
Disease-related risk factors for an increased PF rate after PD
mainly include a non-dilated pancreatic duct, a soft pancreatic
parenchyma and a fatty pancreatic texture.6,11,18–20 A soft pancre-
atic remnant often coexists with a small pancreatic duct increasing
the technical difficulties to perform a duct-to-mucosa anastomo-
sis. The PF rate after PD in patients presenting a soft pancreatic
parenchyma is approximately 25% and is significantly higher than
that observed in patients presenting with a firm pancreas.18,32 In
the present study, the PF rate of 23.4% in patients presenting with
normal/soft pancreatic parenchyma was significantly higher than
observed in patients with a fibrous/hard pancreatic remnant con-
firming that also in a patient with adenocarcinoma the pancreatic
texture predicts the occurrence of PF. However, still one-third of
the patients in this study had a normal or soft pancreas and a
pancreatic duct less than 3 mm, which might explain the relatively
high rates of invagination and ductal stenting used for the
pancreatico-enteric anastomosis in our study.
The benefit of PJ compared with PG after PD still remains a
matter of debate. In this study, the incidence of PF was higher after
PJ compared with PG. Over the past 20 years, there have been four
prospective randomized trials comparing PJ and PG.While three of
these studies have reported no difference in the PF rate, one dem-
Table 5 Multivariate analysis of risk factors for mortality, morbidity
and pancreas-related complications
Relative risk
(95% CI)
P-value
Mortality
Pancreatic fistula (yes vs. no) 5.43 (2.70–10.89) <0.0001
ASA status (III/IV vs. I/II) 3.33 (1.61–6.90) 0.001
Number of RBC (>2 vs. <2) 4.45 (2.15–9.19) <0.0001
Morbidity
Gender (male vs female) 1.50 (1.19–1.90) 0.0009
Number of RBC (>2 vs. <2) 1.47 (1.03–2.11) 0.034
Centre volume (<20 vs. >20) 1.39 (1.09–1.78) 0.0077
Texture of pancreatic parenchyma
(normal vs. fibrous)
1.71 (1.34–2.18) <0.0001
Pancreatic fistula
Diabetes mellitus (absent vs.
present)
2.64 (1.43–4.78) 0.0014
Pancreatic anastomosis (PJ vs. PG) 1.77 (1.20–2.61) 0.0035
Texture of parenchyma (normal
vs. fibrous)
4.43 (3.00–6.55) <0.0001
Centre volume (<10 vs. >10) 1.92 (1.07–3.45) 0.0286
Octreotide administration (yes vs. no) 1.76 (1.22–2.55) 0.0023
Intrabdominal haemorrhage
Pancreatic fistula (yes vs. no) 6.36 (2.81–14.41) 0.0001
Texture of parenchyma (normal
vs. fibrous)
4.14 (1.45–11.78) 0.0076
Type of GJ anastomosis (antecolic
vs. transmesocolic)
3.31 (1.042–10.52) 0.0423
Digestive haemorrhage
Pancreatic fistula (yes vs. no) 3.40 (1.98–5.83) <0.0001
Pre-operative biliary drainage (non
vs. yes)
1.80 (1.00–3.22) 0.0467
Number of lymph node harvested
(<20 vs. >20)
1.79 (1.00–3.20) 0.0491
Pylorus preservation (yes vs. no) 2.29 (1.25–4.19) 0.0073
Delayed gastric emptying
Centre volume (<10 vs. >10) 1.70 (1.13–2.55) 0.0107
Age (>70 vs. <70 years) 1.62 (1.17–2.23) 0.0031
Pylorus preservation (no vs. yes) 1.90 (1.06–3.42) 0.0297
Pancreatic fistula (yes vs. no) 1.80 (1.21–2.67) 0.0034
CI, confidence interval; RBC, red blood cells.
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onstrated a significantly lower rate of PF after PG than PJ (4% vs.
18%).16,49–51 However, a multitude of anastomotic techniques
and definitions for PF were used.50 Much of the actual evidence
supporting PG over PJ comes from single institutional retrospec-
tive studies that use exclusively telescoping or invaginating
techniques.25–28,33,52,53 Several non-randomized comparative studies
have shown a significantly lower PF and relaparotomy rates after
invaginated PG compared with PJ.25–28,33,52 A meta-analysis com-
paring PG and PJ showed a significant decrease in the incidence of
PF and mortality for PG.54 In our study, PJ was identified as an
independent risk factor for PF after PD. While there was no corre-
lation between a particular anastomotic technique for PG and the
reported consistency of the pancreas, however, invagination was
the most common technique used for PG. This may explain the
observed lower rate of PF in patients undergoing PG in our study.
We also observed that PF occurring after PG was associated with a
significantly lower grade and significantly less severe complications
than after PJ. This may be explained by the improved ability to
manage PF after PG owing to the fact that nasogastric tube suction
can be applied to reduce fistula output and the absence of enter-
okinase in the stomach, preventing activation of pancreatic
enzymes. Aranha et al.33 reported a shorter and more favourable
evolution in PF after PG compared with PJ. Oussoultzoglou et al.28
reported a significant reduction in relaparotomy and completion
pancreatectomy rates with PG over PJ. Munoz-Bongrand et al.34
reported that conservative management of PF after PG was suc-
cessful in more than 75% of patients. It has been shown that PF
after PJ increased the use of interventional or operative manage-
ment compared with PJ.28,33 In this study, the overall relaparotomy
rate did not differ between PJ and PG. However, because the study
is underpowered in this regard and there was a lack of uniformity in
centre-related policies concerning relaparotomy for PF a firm con-
clusion cannot be obtained.
PD remains a challenging procedure characterized by a steep
learning curve. Previous studies suggest that after 60 PDs surgeons
improved their peri-operative outcomes in terms of blood loss,
operative time, length of hospital stay and margin status.24
Recently, Pecorelli et al.55 reported that an individual surgeon’s
volume is directly correlated with an increase in the PF rate.
However, low-volume surgeons in high-volume institutions have
morbidity and mortality rates similar to high-volume surgeons,
demonstrating the ability of experienced centres to anticipate and
manage PF-related complications.55 Although we did not evaluate
individual surgeons volume in this study, we found that centres
including less than 20 PD for adenocarcinoma per year experienced
a higher overall morbidity after PF. In addition, low-volume centres
had a statistically significant higher rate of PF and DGE. These
findings are in concordance with previous reports demonstrating
improvement in patient outcomes for high-volume centres with
decreased rates of clinically relevant PF and mortality.22,56
This study’s limitations deserve commentary. First, its retro-
spective design limits the accuracy of our conclusions. Second, the
type of surgical technique used and of the ability and strategies to
manage patients’ complications reflects the diversity in centre and
surgeon expertise and volume. However, our data reflect the
common practice in a large European country where pancreatic
surgery is performed in both academic and community settings. It
shows that the technique of PD has been well standardized and
mortality and morbidity are improved over historical data. Third,
the larger proportion of patients undergoing PJ and lack of ran-
domization may have contributed to the increased number of
complications detected in this subgroup of patients. Lastly, the
inclusion of low-, medium- and high-volume centres might have
introduced a bias towards higher overall and PF-related morbidity
rates. The large cohort of patient and completeness of the col-
lected data support the strength of this study. The results of the
present analysis will hopefully lead to a prospective randomized
study with the ultimate goal of a centralized national programme
for pancreatic surgery.
Conclusions
The present French multicentric retrospective survey on PD for
adenocarinoma found that a soft pancreatic parenchyma, the
absence of pre-operative diabetes, PJ and low volume centres were
independent risk factors for PF. The incidence, the clinical severity as
well as post-operative major complications were significantly higher
after PJ compared with PG. This study confirms the relationship
between PF and the occurrence of major post-operative complica-
tions in this select group of patients and the association between
low-volume centres and higher overall and PF-related morbidity.
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